Azevan Pharmaceuticals, LLC

AZEVAN PHARMACEUTICALS LLC develops pharmaceuticals for the treatment of central nervous system (CNS) disorders. Its focus has been on stress-related affective illness resulting in anxiety and depression, CNS disorders causing aggression, and female health issues. Its lead compound, SRX246, is in a Phase II clinical trial for treatment of Intermittent Explosive Disorder and other mood and behavior disorders.